AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01466530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.
Study NCT01466530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
Study NCT01963429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: \* RFA(radiofrequency ablation )~* RFA electrode: Cool-tip RF ablation system (Covidien plc, 20 Lower Hatch Street Dublin 2, Ireland) and Well-Point RF Electrode (STARmed, Koea)~* performed using either the manufacturer's standard algorithm or an interactive algorithm, with the latter being used when the impedance did not begin to increase at the midinterval of the standard algorithm~* the duration of a single RFA session was 10 min to 15 min.
Study NCT01963429 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy
Description: \* Proton~66 GyE /10 fx, 6.6 GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume),TLV30\<40%,and/orRLV30\<30%)
Study NCT00419146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoic acid (EPA)
Description: Capsules, 2 g per day for 16 weeks
Study NCT00419146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamins E + C
Description: RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
Study NCT00419146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etyl EPA (placebo)
Description: Paraffin oil. Capsules, each 0.5 g.
Study NCT00419146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamins E+C (placebo)
Description: Tablets containing dicalciumphosphate
Study NCT00419146 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vitamins E+C (placebo)
Description: Tablets containing dicalciumphosphate
Study NCT02024568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: See arm description
Study NCT02024568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description
Study NCT03923751 — intervention group
Intervention type: OTHER
Intervention: Invitation to regional anesthesia survey
Description: An invitation letter sent to Head of Anesthesiology and Intensive Care Department of Polish Hospital
Study NCT02218957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended Pouch RYGB
Study NCT02218957 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard RYGB
Study NCT01751399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study NCT04553705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3/Nigella Sativa Oil
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone
Study NCT04553705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3/Nigella Sativa Oil/Indian Costus
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Indian Costus supplements
Study NCT04553705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3/Nigella Sativa Oil/Quinine pills
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Quinine supplementation (1g Quinine)
Study NCT04553705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3/Nigella Sativa Oil/Anise seed capsule
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Anise seed supplementation (450mg anise seed)
Study NCT04553705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Deglycyrrhizinated Licorice 800 mg
Study NCT04553705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Standard protocol care of COVID-19 infection
Study NCT02032550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preference Based Decision Aid
Description: The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.
Study NCT04807855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The cMLP device
Description: There is only one medical device we are testing, so only one intervention.
Study NCT00003865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toremifene
Study NCT05855057 — intervention group
Intervention type: PROCEDURE
Intervention: Flank suspended supine position percutaneous nephrolithotomy
Description: The patients will be placed in the supine position with the shoulder and the buttock will be raised by a 3-l bag of water suspending the flank of the affected side. The body contour will be aligned to the edge of the table. The operating table will be adjusted to the jack knife position, with the tip of the lower part of the table will be slightly lowered. The leg of the affected side of the patent will be straightened dorsally flexed and slightly inner rotated, with the knee of the other side will be flexed. The patients will be then immobilized at the chest and the pelvis with two adherent tapes which crossed each other at the abdomen to form a 'V' shape.
Study NCT05855057 — intervention group
Intervention type: PROCEDURE
Intervention: Supine percutaneous nephrolithotomy group
Description: The patient will remain in the supine position, with the side of interest at the edge of the table, with a small cushion placed under the flank to elevate it 15-20°.
Study NCT05855057 — intervention group
Intervention type: PROCEDURE
Intervention: Prone percutaneous nephrolithotomy group
Description: Prone percutaneous nephrolithotomy. The prone position (PRON) technique followed these classic steps: patients will be placed in a lithotomy position and a ureteral catheter will be inserted through a rigid cystoscope to perform a retrograde pyelogram. The ureteral catheter will be fixed to a Foley catheter, and then the patient will be repositioned to the prone position with pads under their shoulders.
Study NCT00073528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1500 mg orally once a day
Study NCT00073528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg orally once a day
Study NCT00073528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg orally once a day
Study NCT00073528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (which matched with lapatinib tablet)
Study NCT02467283 — intervention group
Intervention type: GENETIC
Intervention: Genom-based whole-genome transcriptomic
Description: Gene expression profiling is a powerful means of generating comprehensive genome-level data sets.
Study NCT01881945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive physiological signal recording on healthy volunteer
Study NCT06011564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reminder function on Android computer tablet
Description: Computer tablet with reminder function
Study NCT02282566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-nutrition beverage
Description: Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter
Study NCT02282566 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Protein-nutrition beverage
Description: Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter
Study NCT03975101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: very small embryonic-like stem cell
Description: Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
Study NCT02039804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Intra-bursal injection
Study NCT02039804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Intra-bursal injection
Study NCT02746133 — intervention group
Intervention type: OTHER
Intervention: Observational study: Supplemented protein-restricted diet
Description: Observational study: Supplemented protein-restricted diet
Study NCT00003702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV
Study NCT00003702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intramuscularly
Study NCT03007979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib at a dose of 125 mg should be taken by mouth with food on a 5 days on/2 days off schedule
Study NCT03007979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.
Study NCT03007979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Patients who are receiving fulvestrant will receive it at a dose of 500 mg as two 5 mL intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
Study NCT03007979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional research biopsy
Description: Patients may consent to paired tumor biopsies at baseline and time of progression.
Study NCT03007979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- and peri-menopausal women only.
Study NCT03007979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Blood will be drawn at the following time points for serum, plasma, cfDNA, and germline DNA (only at baseline):~* Baseline~* C1D15~* C2D1~* Every 2-3 months thereafter (to coincide with imaging studies)~* Time of progression
Study NCT03007979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circulating tumor cell blood draw
Description: -Baseline, cycle 2 day 1, post 2 or 3 months of therapy (to coincide with first tumor imaging), and progression
Study NCT03007979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy (optional)
Description: -Baseline and progression
Study NCT00733954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate spray
Description: Apply twice daily
Study NCT00733954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate ointment
Description: Apply twice daily
Study NCT01406236 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transradial PCI
Description: Transradial PCI
Study NCT01406236 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transfemoral PCI
Description: Transfemoral PCI
Study NCT02522507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowering youth towards employment
Description: Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
Study NCT03286686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: point targets
Description: In the experiences 1 and 2, the participant needs to point different visual targets (LED) in the dark.
Study NCT03286686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tactile stimulation
Description: In the experience 3, a tactile stimulation is applied to the middle finger of the 2 hands. The participant needs to indicate into a microphone when he feels the stimulation.
Study NCT03286686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual images
Description: Target dots or visual images are presented on a computer screen. The participant is required to point to the targets or to react as soon as possible by pressing a response button when they are detected.
Study NCT00482703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: tablets, Oral, 100 mg, once daily
Study NCT00482703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: tablets, Oral, 50 mg, twice daily
Study NCT00225979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Study NCT01056172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and Ribavirin
Description: 1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)~3. Treatment duration: 16 weeks
Study NCT01056172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a and Ribavirin
Description: 1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)~3. Treatment duration: 24 weeks
Study NCT04643080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt
Description: 6 oz. of a commercially available yogurt were provided daily for 12 weeks
Study NCT00602095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 0.025mg tablet vaginally every 4 hour until progress
Study NCT00602095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dinoprostone
Description: 2mg vaginal gel every 6 hours until progress
Study NCT00602095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bard Catheter (balloon catheter)
Description: Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
Study NCT00843518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY451395
Description: 3 mg LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
Study NCT00843518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally twice daily for 12 weeks
Study NCT01473979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical closure of the poststernotomy wound infection
Description: Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.~Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone.
Study NCT04530773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watch VR movies/ Play VR games
Description: The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.
Study NCT00997451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral self-management
Description: Graded activity, pacing, stress reduction, low effort pleasant activities, cognitive coping skills.
Study NCT00997451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom monitoring
Description: Daily symptom via web diary
Study NCT01059110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salicylate ointment
Description: cream, one application every night, for 90 days
Study NCT01059110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
Study NCT01059110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoro-Uracil
Description: cream, one application every night, during 12 hours, for 90 days
Study NCT01059110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: 2 cycles of 5 seconds after obtention of halo of white
Study NCT02580942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic stickers
Description: 36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
Study NCT02580942 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham magnetic stickers
Description: 36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
Study NCT02580942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Description: 72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
Study NCT02580942 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Chinese herbal medicine
Description: 72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
Study NCT03951051 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan Medoxomil 40 mg
Description: Olmesartan Medoxomil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
Study NCT03951051 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olmetec®
Description: Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
Study NCT01391403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemisinin
Description: 400 mg/day
Study NCT01391403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg/day
Study NCT02933099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant+palonosetron+dexamethasone
Description: Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus palonosetron 0.25 mg IV and dexamethasone (20 mg orally on day 1 and 8 mg orally on days 2 and 3)
Study NCT02933099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron+dexamethasone
Description: Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: palonosetron 0.25 mg IV and dexamethasone (12 mg orally on day 1 and 8 mg orally on days 2 and 3)
Study NCT00151983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
Study NCT00151983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
Study NCT01936636 — intervention group
Intervention type: DRUG
Intervention: Fentanyl
Study NCT03456648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: non-vitamin K oral anticoagulant (NOAC)
Study NCT04305275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-324
Description: SAGE-324 oral tablet
Study NCT04305275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAGE-324 Placebo
Description: SAGE-324 matched placebo oral tablet
Study NCT03275571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cCBT intervention
Description: During each 30 minutes sessions, the participants will learn key concepts on depression, then will apply them to the program's main character who suffers from depression, and then will apply those techniques to their own personal challenges.